A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease (PARAISO)

ID: NCT07174310

Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.

Status: Open - Pre Screening is ok

https://clinicaltrials.gov/study/NCT07174310

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease (ROSSINI)

ID: NCT06107426

Brief Summary: Parkinson's disease (PD) is a neurological condition that affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in a real-world setting.

Status: Open - Not Enrolling

https://clinicaltrials.gov/study/NCT06107426

ID: NCT07284784

Brief Summary: This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Status: DBS Enrolling

https://clinicaltrials.gov/study/NCT07284784

Summary: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease (NEULARK)

Status: Enrolling

https://clinicaltrials.gov/study/NCT06680830

ID: NCT06765668

Brief Summary: The primary purpose of this study is to evaluate the efficacy and safety of CREXONT under real-world conditions in participants with Parkinson's disease (PD).

Status: Ongoing

https://clinicaltrials.gov/study/NCT06765668

ID: NCT06944522

Brief Summary: Study BRT-DA01-301 is a Phase 3 multicenter, randomized, sham surgery-controlled, double-blind study to assess the efficacy and safety of bemdaneprocel in approximately 102 adults with Parkinson's Disease (PD).

Status: Enrolling

https://clinicaltrials.gov/study/NCT06944522

ID: NCT04777331

Brief Description: This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Status: Ongoing

https://clinicaltrials.gov/study/NCT04777331

ID: NCT03100149

Brief summary: This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. 

Status: Maintaining

https://clinicaltrials.gov/study/NCT03100149

ID: NCT06773962

Brief summary: The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

Status: Maintaining 

https://clinicaltrials.gov/study/NCT06773962

ID: NCT06937931

Brief summary: The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.

Status: Enrolling

https://clinicaltrials.gov/study/NCT06937931

ID: NCT06568237

Brief summary: A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study (TOPAS-MSA)

Status: Enrolling

https://clinicaltrials.gov/study/NCT06568237

Brief summary:

The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. 

The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Status:

Recruiting - For more information, review the study record:

https://clinicaltrials.gov/study/NCT04477785?term=robert%20hauser&rank=9